Impact of surface coating on postinterventional DWI lesions: A comparative analysis of coated and uncoated FRED and DERIVO flow-diverters in the treatment of intracranial aneurysms

Abstract

Purpose

Recent advancements in flow-diverter (FD) technology have introduced various coating strategies to reduce platelet aggregation and thromboembolic complications in intracranial aneurysm treatment. This study compared postinterventional diffusion-weighted imaging (DWI) lesions, as markers of thromboembolic events, between coated and uncoated FDs.

Methods

A retrospective analysis was conducted on patients treated for intracranial aneurysms between June 2018 and December 2024. The primary outcome was the occurrence of postinterventional DWI + lesions, with periprocedural factors analyzed for their association.

Results

A total of 91 patients with 104 aneurysms were treated with 43 uncoated (n = 30 FRED, n = 13 DERIVO) and 51 coated FDs (n = 36 FREDX, n = 15 DERIVO2Heal). DWI + lesions were observed in 39.5% of uncoated and 54.9% of coated FD cases (p = 0.1). After 1:1 propensity score matching, no significant difference was found (p = 0.131). Contrast stasis (p = 0.025) within aneurysm sac after FD deployment, FD proximal/distal ratio (p = 0.007), FD size (p = 0.047), and intervention duration (p = 0.036) were significantly associated with DWI + lesions. In multivariable analysis, contrast stasis (ORa = 3.7, 95% CI 1.1–11.9, p = 0.029), FD proximal/distal ratio (ORa = 27.8, 95% CI 1.8–426.8, p = 0.017), and older age (ORa = 1.06, 95% CI 1.00–1.11, p = 0.050) increased incidence of DWI + lesions.

Conclusion

In this single-center observational study, coated FRED and DERIVO FDs did not reduce postinterventional DWI + lesions compared to their uncoated counterparts.

Keywords

Flow diverter coating DWI + lesions aneurysm stroke

Introduction

With the first device receiving FDA approval in 2011 for large or wide-necked aneurysms of the internal carotid artery (ICA), flow-diverters (FDs) have become an increasingly utilized and effective treatment option, demonstrating promising long-term aneurysm occlusion rates.^1,2 Constructed as braided stents with high metal coverage, FDs function by inducing flow stagnation and subsequent thrombosis in the aneurysm sac while promoting parent vessel endothelialization at the aneurysm neck. However, the need for effective dual antiplatelet therapy (DAPT) remains a significant drawback of FD treatment, as the high mesh density can otherwise induce platelet activation, potentially leading to in-stent thrombus formation and life-threatening ischemic strokes. A meta-analysis of 1656 FDs from previous generations reported an acute ischemic stroke rate of 5% and delayed ischemic events at 4.2%, highlighting thromboembolic events as a major safety concern despite the use of antiplatelet therapies.³

To reduce the thrombogenicity of FDs without compromising their high metal coverage, FD manufacturers have, in recent years, developed various coating techniques for stent surface modification in their latest products. Preliminary ex vivo and animal studies have demonstrated enhanced hemocompatibility and reduced thrombogenicity achieved through these coating techniques.^4,5 Retrospective observational studies involving small patient cohorts have further indicated the safety and efficacy of surface-modified FDs, even in patients undergoing single antiplatelet therapy (SAPT).^6,7 A randomized multicenter trial aimed at comparing thromboembolic and hemorrhagic complications between coated FDs under SAPT and bare FDs under DAPT is currently ongoing.⁸

To date, only limited studies have compared the postoperative short-term thrombogenicity of coated FDs with their uncoated counterparts, such as Pipeline Flex with Shield Technology versus Pipeline Flex, and have found no significant differences in the incidence of thromboembolic events.⁹ Given the substantial variation in surface modification strategies among FD manufacturers, we conducted a retrospective study to compare coated and uncoated FDs, focusing on short-term thromboembolic events detected via magnetic resonance imaging (MRI). Additionally, we aimed to identify periprocedural factors associated with the occurrence of postinterventional thromboembolic events.

Methods

Study design

This retrospective study analyzed consecutive patients who underwent endovascular treatment of intracranial aneurysms with FDs at a tertiary care center in Germany between June 2018 and December 2024. Ethical approval was obtained from the institutional review board (#15-6331-BO), and the study was conducted in full compliance with the Declaration of Helsinki. Inclusion criteria were patient age over 18 years, FD treatment for intracranial aneurysms, and availability of postinterventional MRI within 3 weeks of the procedure. To facilitate a direct comparison between FDs with and without surface modification, only FDs from the same manufacturer with identical stent designs were included in the analysis.

Patient characteristics and periprocedural factors

Patient baseline characteristics, including age, sex, smoking status, and diabetes mellitus, were documented. For elective cases, patients underwent platelet function analyzer (PFA) testing and were prescribed DAPT with 100 mg aspirin and 75 mg clopidogrel daily for 1 week prior to the procedure. In cases where clopidogrel resistance was detected using vasodilator-stimulated phosphoprotein blood (VASP) testing, clopidogrel was replaced with either 90 mg ticagrelor twice daily or 10 mg prasugrel once daily. DAPT was continued for 6 months, after which aspirin was maintained for life. In acute cases of subarachnoid hemorrhage (SAH), bodyweight-adapted tirofiban was administered intravenously during the neurointervention as a bridging therapy before transitioning to DAPT.

Aneurysms were categorized as either unruptured or ruptured. Additionally, a distinction was made between untreated aneurysms and those with prior treatments, such as coils and/or stents. Aneurysm dimensions were assessed using three-dimensional rotational angiography, with measurements taken for the aneurysm neck, sac height, and sac width. Dome-to-neck and ASPECT ratios were calculated accordingly.¹⁰ Parent vessel diameters were measured at the proximal and distal landing zones of the FD as well as at the aneurysm neck. Stenosis within the stented segment was classified as less than 30%, 30% to 70%, or greater than 70%, based on a comparison of the narrowest vessel segment being stented with the vessel diameter 5 mm proximally.

Aneurysms were further categorized by morphology as saccular or fusiform and by location as sidewall, side-branch, or terminus aneurysms (e.g., carotid T or basilar apex). In cases where a single FD covered multiple aneurysms, the largest aneurysm was designated as the index aneurysm for analysis.

Flow-diverter deployment-related variables

All patients underwent general anesthesia. A bolus of heparin (50 U/kg) was administered intravenously, followed by additional boluses of 1000 units every hour. Several key parameters related to FD deployment were assessed, including complete opening of the proximal and distal stent ends, full neck coverage, and complete wall apposition along the entire device length. Aneurysm filling and blood stasis within the sac were evaluated before and after FD deployment using the O’Kelly–Marotta grading scale (OKM).¹¹

Procedures were classified based on whether the FD was implanted alone or in combination with concomitant coiling. Coils from two different manufacturers were mainly used: bare platinum and hydrogel-coated ones (MicroVention, Tustin, CA, USA; Stryker, Venlo, Netherlands). Intraprocedural thromboembolic events and in-stent thrombosis were systematically recorded. The duration of the intervention was defined as the time interval between the first and last digital subtraction angiography (DSA) acquisitions.

All FDs were implanted by a consistent team of three neurointerventionists: one with over 25 years of interventional experience and two with approximately 6 years each. The procedures were fairly evenly distributed among the three operators.

Postinterventional MRI evaluation

Generally, a postinterventional baseline MRI was performed for all patients before discharge. Diffusion-weighted imaging (DWI) was used to identify ischemic lesions, defined as brain tissue areas exhibiting high signal intensity on b1000 sequences with corresponding reversed signal intensity on the apparent diffusion coefficient (ADC) map. DWI + lesions were correlated with the vascular territories corresponding to the implanted FD. The total number of lesions was recorded, with the largest lesion measured in millimeters. Clinically silent DWI + lesions were defined as those without newly manifested neurological deficits. Postprocedural MRI scans were performed using either a 1.5-T (Siemens, Aera, Erlangen, Germany) or 3-T (Siemens, Skyra, Erlangen, Germany) scanner with a standardized DWI Protocoll across both systems to ensure comparability. The neuroimaging analysis was independently performed by two board-certified neuroradiologists (YL, CD), who were blinded to the type of implanted FD.

Study outcomes

The primary outcome of the study was the occurrence of postinterventional DWI + lesions. We compared the presence of DWI + lesions between patients treated with coated and uncoated FDs. Additionally, all periprocedural factors were analyzed to assess their association with the occurrence of DWI + lesions.

As a secondary outcome, the prevalence of hyperacute thromboembolic events, including in-stent thrombosis and peripheral thromboemboli, was compared between the coated and uncoated FD groups. Finally, we evaluated the clinical impact of DWI + lesions by correlating their presence with patients’ neurological status at discharge.

Statistical analysis

Categorical variables were summarized as frequencies and percentages, while numerical variables were presented as means with standard deviations. Comparisons of categorical variables were conducted using the Chi-squared test or Fisher's exact test, while numerical variables were analyzed using Student's t-test for normally distributed data and the Mann–Whitney U test for non-normally distributed data.

Individual propensity scores (PS) were calculated using a multivariable logistic regression model, with coated FD as the response variable. Based on these propensity scores, 1:1 matching was performed to create two comparable FD groups, one with and one without coating. A total of 35 periprocedural covariates were included in the regression model to assess their association with the occurrence of DWI + lesions. In an initial model, the FD proximal-to-distal diameter ratio showed a disproportionately high effect estimate, prompting further evaluation. To address potential bias, multicollinearity was assessed using the variance inflation factor (VIF), and only variables with VIF < 5 were retained in the final model. Additionally, cases with extreme values (>3 standard deviations from the mean) for continuous predictors were excluded to reduce the influence of outliers.

Additionally, Pearson correlation analysis was used to evaluate the relationship between periprocedural covariates and the number of DWI + lesions.

All statistical analyses were conducted using SPSS (version 29, IBM, Armonk, NY, USA), with a p-value < 0.05 considered statistically significant.

Results

Baseline patient and aneurysm characteristics

A total of 99 patients with 114 intracranial aneurysms underwent FD treatment between June 2018 and December 2024. Of these, 91 patients with 104 aneurysms treated with 94 FDs met the inclusion criteria and were included in the final analysis. The mean patient age was 55.7 years (±10.4), with a majority being female (76%, 71/94). Smoking and diabetes mellitus were present in 57 (61%, 57/94) and 12 (13%, 12/94) patients, respectively (Table 1). The most used DAPT regimen was aspirin + clopidogrel (78.7%, 74/94), followed by aspirin + ticagrelor (14.9%, 14/94) and aspirin + prasugrel (6.4%, 6/94). Patients in the coated FD group were significantly older (58 vs. 53 years, p = 0.02); however, after 1:1 propensity score matching, this age difference was no longer statistically significant.

Table 1.

Baseline patient and aneurysm characteristics.

	Overall (N = 94)	Uncoated FD (N = 43)	Coated FD (N = 51)	p	PS-matching
	Overall (N = 94)	Uncoated FD (N = 43)	Coated FD (N = 51)	p	Uncoated FD (N = 42)	Coated FD (N = 42)	p
Patient age (years)	55.7 ± 10.4	53.0 ± 9.3	58.0 ± 10.8	0.020	53.3 ± 9.2	57.0 ± 10.1	0.081
Female sex	71 (75.5%)	33 (76.7%)	38 (74.5%)	0.802	32 (76.2%)	31 (73.8%)	0.801
Comorbidities
Smoking	57 (60.6%)	30 (69.8%)	27 (52.9%)	0.142	29 (69.0%)	21 (50.0%)	0.119
Diabetes	12 (12.8%)	4 (9.3%)	8 (15.7%)	0.267	4 (9.5%)	5 (11.9%)	1.0
Previous SAH	19 (20.2%)	4 (9.3%)	15 (29.4%)	0.020	4 (9.5%)	9 (21.4%)	0.227
Recurrent aneurysm/Pretreatment	19 (20.2%)	7 (16.3%)	12 (23.5%)	0.383	7 (16.7%)	10 (23.8%)	0.415
Aneurysm type				0.236			0.211
Sidewall	71 (75.5%)	36 (83.7%)	35 (68.6%)		35 (83.3%)	28 (66.7%)
Terminus	3 (3.2%)	1 (2.3%)	2 (3.9%)		1 (2.4%)	2 (4.8%)
Sidebranch	20 (21.3%)	6 (14.0%)	14 (27.5%)		6 (14.3%)	12 (28.6%)
Aneurysm location				0.467			0.266
Anterior circulation	78 (83.0%)	37 (86.0%)	41 (80.4%)		36 (85.7%)	32 (76.2%)
ICA - cavernosal	11 (11.7%)	6 (2.3%)	5 (9.8%)		5 (11.9%)	4 (9.5%)
ICA - paraophthalmic	50 (53.2%)	28 (14.0%)	22 (43.1%)		28 (66.7%)	16 (38.1%)
ICA - Pcom	11 (11.7%)	1 (65.1%)	10 (19.6%)		1 (2.4%)	8 (19.0%)
ICA - ACho	4 (4.3%)	0 (0%)	4 (7.8%)		0 (0%)	4 (9.5%)
MCA – M1	1 (1.1%)	1 (2.3%)	0 (0%)		1 (2.4%)	0 (0%)
ACA - Pericallosa	1 (1.1%)	1 (2.3%)	0 (0%)		1 (2.4%)	0 (0%)
Posterior circulation	16 (17.0%)	6 (14.0%)	10 (19.6%)		6 (14.3%)	10 (23.8%)
VA – V4	6 (6.4%)	3 (7.0%)	3 (5.9%)		3 (7.1%)	3 (7.1%)
PICA	4 (4.3%)	2 (4.7%)	2 (3.9%)		2 (4.8%)	2 (4.8%)
BA - trunk	6 (6.4%)	1 (2.3%)	5 (9.8%)		1 (2.4%)	5 (11.9%)
Aneurysm morphology				1.0			1.0
Saccular	86 (91.5%)	39 (90.7%)	47 (92.2%)		38 (90.5%)	38 (90.5%)
Fusiform	8 (8.5%)	4 (9.3%)	4 (7.8%)		4 (9.5%)	4 (9.5%)
Aneurysm size
Dome width (mm)	8.9 ± 4.8	9.1 ± 4.0	8.7 ± 5.4	0.703	8.9 ± 4.0	8.9 ± 4.9	0.979
Height (mm)	8.5 ± 5.0	8.6 ± 4.3	8.4 ± 5.7	0.847	8.5 ± 4.3	8.6 ± 5.6	0.960
Neck width (mm)	5.9 ± 4.0	6.3 ± 3.7	5.7 ± 4.3	0.453	6.2 ± 3.7	5.8 ± 4.5	0.672
D/N ratio	1.6 ± 0.7	1.6 ± 0.5	1.7 ± 0.8	0.530	1.6 ± 0.6	1.7 ± 0.8	0.386
ASPECT ratio	1.6 ± 0.8	1.5 ± 0.7	1.6 ± 0.8	0.615	1.5 ± 0.7	1.6 ± 0.9	0.552
Parent artery diameter (mm)
Proximal	4.0 ± 0.7	4.0 ± 0.6	4.0 ± 0.8	0.670	4.0 ± 0.6	4.0 ± 0.9	0.850
At aneurysm	4.0 ± 1.9	4.2 ± 2.7	3.8 ± 0.8	0.295	4.2 ± 2.8	3.8 ± 0.8	0.286
Distal	3.4 ± 0.6	3.4 ± 0.6	3.5 ± 0.7	0.563	3.4 ± 0.6	3.5 ± 0.7	0.610
Mean	3.8 ± 0.8	3.8 ± 0.9	3.8 ± 0.7	0.561	3.9 ± 0.9	3.7 ± 0.7	0.475
Parent artery stenosis	9 (9.6%)	4 (9.3%)	5 (9.8%)	1.0	4 (9.5%)	2 (4.8%)	0.676
Antiplatelet regimen				0.141			0.266
ASA + clopidogrel	74 (78.7%)	37 (86.0%)	37 (72.5%)		36 (85.7%)	31 (73.8%)
ASA + ticagrelor	14 (14.9%)	3 (7.0%)	11 (21.6%)		3 (7.1%)	8 (19.0%)
ASA + prasugrel	6 (6.4%)	3 (7.0%)	3 (5.9%)		3 (7.1%)	3 (7.1%)

Abbreviation: SAH = Subarachnoid hemorrhage; ICA = internal carotid artery; Pcom = posterior communicanting artery; Acho = anterior choroid artery; MCA = middle cerebral artery; M1 = M1 branch; ACA = anterior cerebral artery; VA = vertebral artery; V4 = V4 segment; PICA = posterior inferior cerebellar artery; BA = basilar artery; D/N ratio = dome/neck ratio; ASA = Acetylsalicylic acid.

Among the 94 index aneurysms, 86 (91.5%, 86/94) were saccular, and 19 (20%, 19/94) had a history of rupture. Only 3 aneurysms (3.3%, 3/94) were treated in the acute setting of subarachnoid hemorrhage (SAH). Additionally, 19 aneurysms (20%, 19/94) had undergone previous treatment before FD implantation. The majority (83%, 78/94) were located in the anterior circulation, with most classified as sidewall aneurysms (76%, 71/94). The paraophthalmic segment of the ICA was the most frequently treated location (53.2%, 50/94).

The mean aneurysm width was 8.9 mm (±4.8), height 8.5 mm (±5.0), and neck 5.9 mm (±4.0). The mean parent artery diameters were 4.0 mm (±0.7) at the proximal FD landing zone, 4.0 mm (±1.9) at the aneurysm neck, and 3.4 mm (±0.6) at the distal FD landing zone (see Supplementary Materials).

Procedural factors and thromboembolic complications

Of the 94 implanted FDs, 30 were FRED (Flow-Redirection Endoluminal Device; MicroVention, Aliso Viejo, CA, USA) as uncoated bare FDs, and 36 were FREDX as coated devices. Additionally, 13 were DERIVO2/DERIVO (DERIVO; Acandis, Pforzheim, Germany) as uncoated FDs, while 15 were DERIVO2Heal as coated ones (Table 2). The mean FD size was 4.3 mm (±0.6), with a mean length of 19.2 mm (±7.0).

Table 2.

Procedural characteristics and complications.

	Overall (N = 94)	Uncoated FD (N = 43)	Coated FD (N = 51)	p	PS Matching
	Overall (N = 94)	Uncoated FD (N = 43)	Coated FD (N = 51)	p	Uncoated FD (N = 42)	Coated FD (N = 42)	p
FD types				1.0			0.811
FRED FD	66 (70.2%)	30 (69.8%)	36 (70.6%)		29 (69.0%)	30 (71.4%)
DERIVO FD	28 (29.8%)	13 (30.2%)	15 (29.4%)		13 (31.0%)	12 (28.6%)
FD diameter (mm)	4.3 ± 0.6	4.4 ± 0.6	4.3 ± 0.6	0.833	4.4 ± 0.6	4.4 ± 0.6	0.863
FD length (mm)	19.2 ± 7.0	20.2 ± 8.6	18.3 ± 5.1	0.177	20.0 ± 8.5	17.8 ± 4.6	0.161
FD proximal/distal ratio	1.2 ± 0.2	1.2 ± 0.3	1.2 ± 0.2	0.457	1.2 ± 0.3	1.2 ± 0.2	0.438
Additional Coiling	31 (33.0%)	13 (30.2%)	18 (35.3%)	0.603	13 (31.0%)	14 (33.3%)	0.815
Proximal end completely open	92 (97.9%)	42 (97.7%)	50 (98.0%)	1.0	41 (97.6%)	41 (97.6%)	1.0
Distal end completely open	94 (100%)	43 (100%)	51 (100%)	N/A	42 (100%)	42 (100%)	N/A
Complete wall apposition	79 (84.0%)	37 (86.0%)	42 (82.4%)	0.626	36 (85.7%)	34 (81.0%)	0.558
Complete neck coverage	90 (95.7%)	41 (95.3%)	49 (96.1%)	1.0	40 (95.2%)	40 (95.2%)	1.0
Thrombus in FD	1 (1.1%)	0 (0%)	1 (2.0%)	1.0	0 (0%)	1 (2.4%)	1.0
Length of intervention (min)	115 ± 68	117 ± 74	113 ± 63	0.797	115 ± 74	115 ± 67	0.999
OKM before intervention				0.452			0.493
A	82 (87.2%)	38 (88.4%)	44 (86.3%)		37 (88.1%)	36 (85.7%)
B	11 (11.7%)	4 (9.3%)	7 (13.7%)		4 (9.5%)	6 (14.3%)
C	1 (1.1%)	1 (2.3%)	0 (0%)		1 (2.4%)	0 (0%)
OKM after intervention				0.269			0.185
A	28 (29.8%)	14 (32.6%)	14 (27.5%)		14 (33.3%)	11 (26.2%)
B	53 (56.4%)	24 (55.8%)	29 (56.9%)		23 (54.8%)	26 (61.9%)
C	9 (9.6%)	5 (11.6%)	4 (7.8%)		5 (11.9%)	2 (4.8%)
D	4 (4.3%)	0 (0%)	4 (7.8%)		0 (0%)	3 (7.1%)
Stasis after intervention				0.730			0.960
1	27 (28.7%)	11 (25.6%)	16 (31.4%)		11 (26.2%)	11 (26.2%)
2	17 (18.1%)	9 (20.9%)	8 (15.7%)		9 (21.4%)	8 (19.0%)
3	50 (53.2%)	23 (53.5%)	27 (52.9%)		22 (52.4%)	23 (54.8%)
Thromboembolism in final run	1 (1.1%)	1 (2.3%)	0 (0%)	0.457	1 (2.4%)	0 (0%)	1.0
Procedural thromboembolic events	5 (5.3%)	3 (7.0%)	2 (3.9%)	0.657	1 (2.4%)	1 (2.4%)	1.0
Presence of DWI lesions	45 (47.9%)	17 (39.5%)	28 (54.9%)	0.137	16 (38.1%)	22 (52.4%)	0.188
Average number of DWI lesions	4.9 ± 4.3	3.4 ± 2.7	4.2 ± 5.1	0.543	3.4 ± 2.8	4.1 ± 5.5	0.664
Size of biggest lesion (mm)	6.9 ± 5.7	5.7 ± 3.1	7.6 ± 6.8	0.278	5.9 ± 3.1	7.6 ± 6.8	0.341
Symptomatic ischemic lesions	5 (5.3%)	0 (0%)	5 (9.8%)	0.060	0 (0%)	4 (9.5%)	0.116

Abbreviation: FD = Flow Diverter; FRED = Flow-Redirection Endoluminal Device; OKM = O’Kelly–Marotta grading scale; DWI = Diffusion-weighted imaging.

Concomitant coiling was performed in one-third of all cases. Significant stasis (OKM 3) of the contrast agent at final angiographic control was observed in 53% of cases. The median intervention time was 114 minutes (±6.8). There was one case of intraprocedural hyperacute peripheral thromboembolism with FRED and one case of in-stent thrombosis with FREDX.

Postinterventional DWI + lesions

The median time interval between neurointervention and MRI was 46 hours (±67). DWI + lesions were observed in 37% of FRED, 58% of FREDX, 46% of DERIVO/DERIVO2, and 47% of DERIVO2Heal cases (Figure 1).

Figure 1.

DWI + lesion in a 45-year-old patient following treatment with flow-diverter. (a, b) Saccular supraophthalmic aneurysm of the right ICA shown in 3D rotational angiography and DSA. (c) Flow-diverter (FRED) implantation. (d) DWI + lesion in the right temporal lobe detected 21 hours postimplantation.

The prevalence of DWI + lesions was slightly higher in the coated FD group compared to the uncoated group (55% vs. 40%, p = 0.137 for the unmatched comparison; 52% vs. 38%, p = 0.188 after propensity score matching) (Table 2).

Among the 35 periprocedural factors tested in the univariate analysis, FD size, proximal/distal landing zone ratio, post-deployment contrast stasis within the aneurysm sac (OKM > 1), and intervention duration were significantly different between the coated and uncoated groups (see Supplementary Materials). In the multivariable logistic regression analysis, after adjusting for confounders (Table 3), increased patient age (ORa = 1.06, 95% CI 1.00–1.11, p = 0.050), a higher proximal/distal landing zone ratio (ORa = 27.8, 95% CI 1.8–426.8, p = 0.017), and post-deployment contrast stasis (ORa = 3.7, 95% CI 1.1–11.9, p = 0.029) were significantly associated with an increased likelihood of DWI + lesions. No association was found between the occurrence of DWI + lesions and FD coating status.

Table 3.

Multivariate logistic regression analysis on the presence of DWI lesions.

Parameter	VIF	ORa (95% CI)	p
Patient age	1.100	1.06 (1.00–1.11)	0.050
Mean parent artery diameter	1.071	1.9 (0.8–4.6)	0.130
FD length	1.179	1.02 (0.92–1.12)	0.724
FD proximal-to-distal ratio	1.048	27.8 (1.8–426.8)	0.017
Postinterventional stasis	1.112	3.7 (1.1–11.9)	0.029
Length of intervention	1.048	1.0 (0.99–1.01)	0.352

Abbreviation: ORa = Odds Ratio; FD = Flow-Diverter; VIF = variance inflation factor.

Pearson correlation analysis showed that patient age (ρ = 0.289, p = 0.005), aneurysm dome height (ρ = 0.212, p = 0.04), and FD proximal/distal ratio (ρ = 0.297, p = 0.004) were significantly correlated with the number of DWI + lesions (see Supplementary Materials).

Postprocedural neurological outcomes of patients

Of the 94 FD cases, newly developed neurological deficits were observed in 5 patients at discharge (5%, 5/94). Among these, 4 cases exhibited acute onset within 24 hours, while 1 patient developed delayed symptoms after 8 days. Corresponding DWI + lesions were present in all symptomatic cases (11%, 5/45), whereas the remaining lesions were clinically silent (89%, 40/45).

Patients without DWI + lesions did not exhibit any new neurological symptoms at discharge. However, two patients (4%, 2/49) experienced delayed hemorrhagic strokes with parenchymal hematoma occurring 3 and 5 days postprocedure, respectively (Figure 2).

Figure 2.

Delayed hemorrhagic stroke in a 63-years-old patient. (a) Presence of acute SAH on CT. (b) DSA showing aneurysm of left anterior choroid artery. (c) Aneurysm treatment with loose coil package for preservation of anterior choroid artery. (d) Staged aneurysm treatment with flow-diverter after 34 days. (e) Absence of any DWI lesions at patient's discharge. (f) Acute onset of right-sided arm-dominant hemiparesis due to acute parenchymal hematoma 3 days after discharge.

Discussion

The main finding of this single-center observational study with a limited patient number was that coated FRED and DERIVO FDs under DAPT were not associated with a reduction in postinterventional DWI + lesions compared to their bare metal counterparts. Instead, advanced patient age, contrast-agent stasis within the aneurysm sac after FD deployment, and a high FD proximal/distal ratio were significantly correlated with the occurrence of DWI + lesions.

Although most DWI + lesions remained clinically silent, efforts to minimize them remain crucial, as 11% of cases resulted in neurological impairment. As Goyal et al. highlighted, the brain warrants protection from even minor injury, especially given our limited understanding of periprocedural DWI lesions.¹² In our study, symptomatic DWI + lesions were defined as newly occurring neurological deficits, although this does not capture the full spectrum of brain functions, such as cognition.

A key question in FD treatment is the origin of these lesions. The incidence of DWI + lesions following FD implantation is markedly higher than that observed in diagnostic cerebral angiography,¹³ and unlike diagnostic angiography, some of these lesions were symptomatic. Our results suggest that coating technology did not reduce DWI + lesion incidence, consistent with findings from Cortez et al., who reported similar rates between coated and uncoated FDs (62% in Pipeline Shield vs. 61% in Pipeline Flex).⁹ Another study investigating the coated p48-MW-HPC device found an even higher DWI + rate (70%).¹⁴ These findings suggest that, regardless of coating strategy, additional surface modifications do not necessarily reduce DWI + lesions under DAPT. A study of significant clinical relevance, comparing coated FDs under SAPT with uncoated counterparts under DAPT, is still ongoing.⁸

The prevalence of DWI + lesions in both the coated and uncoated groups (52% vs. 38% after propensity score matching) in our study was lower than previously reported in the literature. This may be partly explained by structural differences between different FDs and their specific coating techniques (see Supplementary Materials), which warrants further investigation. The time interval between intervention and MRI likely also influences detection rates. Additionally, MR technical factors such as differences in MR vendors, field strength, slice thickness, and applied b-values of DWI among studies may have contributed to the observed variability.

Our results indicate that postinterventional DWI + lesions cannot be solely attributed to the intervention or the FD itself. Instead, we hypothesize that a portion of these lesions may originate from thromboemboli within the aneurysm sac. Post-deployment contrast-agent stasis (OKM 2 or higher) was a strong predictor of DWI + lesions (ORa = 3.7, 95% CI 1.1–11.9, p = 0.029). Stasis reflects reduced flow velocity, decelerated inflow rates, and lower shear stress, all of which promote intra-aneurysmal thrombus formation.^15,16 While such pro-thrombotic hemodynamic changes are desirable for aneurysm occlusion, they may also facilitate thrombus escape before endothelialization is complete, leading to DWI + lesions. Supporting this hypothesis, aneurysm dome height was significantly correlated with the number of DWI + lesions (ρ = 0.212, p = 0.04), likely reflecting the proportional relationship between aneurysm dome size, intra-aneurysmal thrombus formation, and distal thromboembolism.

Another key finding was that a higher FD proximal/distal ratio was strongly associated with both the likelihood (ORa = 27.8, 95% CI 1.8–426.8, p = 0.017) and number of DWI + lesions (ρ = 0.297, p = 0.004).

Proper FD sizing is crucial for optimal flow diversion at the aneurysm neck. Oversizing can increase stent porosity and cell size, potentially diminishing the flow-diverting effect and increasing the risk of in-stent stenosis and braid deformation.^17,18,19 A higher proximal/distal ratio, often a consequence of FD oversizing, may lead to increased porosity at the aneurysm neck, facilitating microthrombus escape from the sac.²⁰ Additionally, greater diameter discrepancies between the FD and distal landing zone may enlarge stent cell openings at transition zones, resulting in reduced metal coverage and an increased risk of thromboembolism.²¹ In the multivariable analysis, the proximal-to-distal diameter ratio of the FD remained a significant predictor of DWI + lesion occurrence (ORa = 27.8; 95% CI: 1.8–426.8; p = 0.017). Despite the large effect size, the low variance inflation factor (VIF = 1.048) and the robustness of the association after excluding outliers argue against substantial multicollinearity or undue influence from extreme values. However, the wide confidence interval highlights statistical imprecision related to the limited sample size and number of events. Therefore, the observed association should be interpreted with caution and warrants validation in larger studies.

Furthermore, increased patient age was significantly correlated with DWI + lesion occurrence, a finding consistent with multiple previous studies.^13,22–24 Since patient age is an immutable factor and post-deployment contrast stasis is often desirable for aneurysm occlusion,¹⁵ optimizing FD sizing remains the most critical modifiable factor for reducing short-term thromboembolic complications.

However, one should keep in mind that an unremarkable postprocedural MRI does not guarantee a complication-free course, as two patients in our study experienced intracerebral hemorrhages after hospital discharge.

The main limitations of our study include its retrospective, single-center design and the inclusion of two different FD models. Additionally, uncoated FDs were primarily used before 2022, while coated devices were predominantly implanted thereafter. As operator experience increased over time, implantation quality may have improved with coated devices, introducing a potential selection bias. However, since neither the specific FD model nor the coating status was associated with the occurrence of DWI + lesions, these factors are unlikely to compromise the validity of our findings. Nevertheless, additional data, particularly from prospective studies, are needed to directly compare uncoated FDs under DAPT with coated FDs under SAPT. Furthermore, the lack of randomization in assigning patients to treatment groups introduces the potential for intergroup comparisons to be influenced by unmeasured confounders not captured in the dataset. To mitigate this, we utilized patient matching and multivariable regression models to reduce the impact of the key confounders identified within our analysis.

Conclusion

In this single-center observational study, coated FRED and DERIVO FDs did not reduce postinterventional DWI + lesions compared to their uncoated counterparts. Contrast stasis within aneurysm sac after FD deployment, higher FD proximal/distal ratio of landing zones, and older age of patient increased incidence of postinterventional DWI + lesions.

Supplemental Material

sj-docx-1-ine-10.1177_15910199251367504 - Supplemental material for Impact of surface coating on postinterventional DWI lesions: A comparative analysis of coated and uncoated FRED and DERIVO flow-diverters in the treatment of intracranial aneurysms

Supplemental material, sj-docx-1-ine-10.1177_15910199251367504 for Impact of surface coating on postinterventional DWI lesions: A comparative analysis of coated and uncoated FRED and DERIVO flow-diverters in the treatment of intracranial aneurysms by Christoph Ziegenfuß, Natalie van Landeghem, Adrian Engel, Ramazan Jabbarli, Philipp Dammann, Ulrich Sure, Michael Forsting, Isabel Wanke, Lukas Goertz, Christoph Kabbasch, Cornelius Deuschl and Yan Li in Interventional Neuroradiology

Footnotes

ORCID iDs

Christoph Ziegenfuß

Natalie van Landeghem

Lukas Goertz

Cornelius Deuschl

Ethics approval

This study was approved by Ethics Committee of the University of Duisburg-Essen (#15-6331-BO) and conducted in accordance with the Declaration of Helsinki. Informed consent was waived by the Ethics Committee.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Supplemental material

Supplemental material for this article is available online.

References

Becske

Kallmes

Saatci

, et al. Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial. Radiology 2013; 267: 858–868.

Shehata

Ibrahim

Ghozy

, et al. Long-term outcomes of flow diversion for unruptured intracranial aneurysms: a systematic review and meta-analysis. J Neurointerv Surg 2023; 15: 898–902.

Yang

Liu

, et al. Flow-diverter devices in the treatment of intracranial aneurysms: a meta-analysis and systematic review. Neuroradiol J 2016; 29: 66–71.

Cortese

Forestier

Bardet

, et al. Preclinical in vitro and in vivo results of the new silk vista flow diverter with P8RI coating. J Neurointerv Surg 2024; 17: 775–781.

Girdhar

Ubl

Jahanbekam

, et al. Thrombogenicity assessment of pipeline, pipeline shield, derivo and P64 flow diverters in an in vitro pulsatile flow human blood loop model. eNeurologicalSci 2019; 14: 77–84.

Hellstern

Aguilar Pérez

Henkes

, et al. Use of a p64 MW flow diverter with hydrophilic polymer coating (HPC) and prasugrel single antiplatelet therapy for the treatment of unruptured anterior circulation aneurysms: safety data and short-term occlusion rates. Cardiovasc Intervent Radiol 2022; 45: 1364–1374.

Uysal

Cay

Balcı

, et al. Initial experience with the derivo 2Heal flow diverter under standard or reduced-dose single antiplatelet therapy. AJNR Am J Neuroradiol 2024; 45: 1038–1043.

Pierot

Lamin

Barreau

, et al. Coating (coating to optimize aneurysm treatment in the new flow diverter generation) study. The first randomized controlled trial evaluating a coated flow diverter (p64 MW HPC): study design. J Neurointerv Surg 2023; 15: 684–688.

Cortez

Benalia

VHC

Sauvageau

, et al. Diffusion-weighted imaging lesions after intracranial aneurysm treatment with pipeline flex and pipeline flex with shield technology: a retrospective cohort analysis. J Neurointerv Surg 2024; 16: 385–391.

10.

Weir

Amidei

Kongable

, et al. The aspect ratio (dome/neck) of ruptured and unruptured aneurysms. J Neurosurg 2003; 99: 447–451.

11.

O'Kelly

Krings

Fiorella

, et al. A novel grading scale for the angiographic assessment of intracranial aneurysms treated using flow diverting stents. Interv Neuroradiol 2010; 16: 133–137.

12.

Goyal

Ganesh

Tymianski

, et al.

Iatrogenic diffusion-weighted imaging lesions: what is their impact and how can it be measured?

Stroke 2021; 52: 1929–1936.

13.

Schinz

Zimmermann

Göttler

, et al. Incidence, clinical significance, and longitudinal signal characteristics of ischemic lesions related to diagnostic cerebral catheter angiography. Cardiovasc Intervent Radiol 2023; 46: 921–928.

14.

Pierot

Soize

Cappucci

, et al. Surface-modified flow diverter p48-MW-HPC: preliminary clinical experience in 28 patients treated in two centers. J Neuroradiol 2021; 48: 195–199.

15.

Mut

Raschi

Scrivano

, et al. Association between hemodynamic conditions and occlusion times after flow diversion in cerebral aneurysms. J Neurointerv Surg 2015; 7: 286–290.

16.

Stahl

Marsh

LMM

Thormann

, et al. Assessment of the flow-diverter efficacy for intracranial aneurysm treatment considering pre- and post-interventional hemodynamics. Comput Biol Med 2023; 156: 106720.

17.

Mut

Cebral

. Effects of flow-diverting device oversizing on hemodynamics alteration in cerebral aneurysms. AJNR Am J Neuroradiol 2012; 33: 2010–2016.

18.

Matanov

Vladev

Sirakov

, et al. The significance of stent sizing for parent vessel stenosis after flow diversion of MCA bifurcation aneurysms. Interv Neuroradiol 2024. DOI: https://doi.org/10.1177/15910199241285503.

19.

Popica

Cortese

Oliver

, et al. Flow diverter braid deformation following treatment of cerebral aneurysms: incidence, clinical relevance, and potential risk factors. J Neurointerv Surg 2024; 17: 864–869.

20.

Kim

Yang

, et al. Quantitative analysis of hemodynamic changes induced by the discrepancy between the sizes of the flow diverter and parent artery. Sci Rep 2024; 14: 10653.

21.

Gentric

Darsaut

Makoyeva

, et al. The success of flow diversion in large and giant sidewall aneurysms may depend on the size of the defect in the parent artery. AJNR Am J Neuroradiol 2014; 35: 2119–2124.

22.

Brandes

Fleming

Busse

. Endothelial aging. Cardiovasc Res 2005; 66: 286–294.

23.

Tokunaga

Hatano

Nakahara

, et al. Factors associated with postprocedural diffusion-weighted imaging-positive lesions in endovascular treatment for unruptured cerebral aneurysms. World Neurosurg 2019; 130: e457–ee62.

24.

Kesseler

Tafelmeier

Nikoubashman

, et al. Frequency and pattern of MRI diffusion restrictions after diagnostic catheter neuroangiography. Tomography 2023; 9: 1010–1018.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB